Product Description
Onsero is developing a 5HT2A Agonist for the treatment of neurological disorders such as depression, anxiety and substance abuse (https://patents.google.com/patent/US20240425503A1/en)
Mechanisms of Action: 5-HT2A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Onsero
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Depressive Disorder|Generalized anxiety disorder|Substance Abuse Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|